title: A model to estimate the outcome of prostate cancer photodynamic therapy with TOOKAD Soluble WST11.
abstract: Interstitial photodynamic therapy is becoming an interesting modality to treat some early stage prostate cancers. A light-sensitive drug is injected to the patient and activated by light using optical fibres inserted inside the prostate. In this work, we were interested in the characterization of the light action model for the WST11 (Tookad® Soluble) drug. A retrospective analysis was performed on results from 28 patients enrolled in phase I and II trials with the WST11 drug. A drug dose of 4 mg/kg patient, dose light of 200 J cm(-1) and wavelength of 753 nm were used. Correlation between the illuminated volume and the obtained necrosis, measured at day 7 MR images, was clearly established. This result suggests that photodynamic therapy planning is possible based on this model.
authors.affiliation: Inserm U703, 152 rue du Docteur Yersin, 59120 Loos, France. Université Lille Nord de France, F-59000 Lille, France. CHU Lille, F-59000 Lille, France. n-betrouni@chru-lille.fr
authors.forename: Nacim
authors.initials: N
authors.lastname: Betrouni
authors.forename: Renaud
authors.initials: R
authors.lastname: Lopes
authors.forename: Philippe
authors.initials: P
authors.lastname: Puech
authors.forename: Pierre
authors.initials: P
authors.lastname: Colin
authors.forename: Serge
authors.initials: S
authors.lastname: Mordon
mesh_terms: D001429:Bacteriochlorophylls / Q000737:chemistry* / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008954:Models, Biological; D010778:Photochemotherapy / Q000379:methods*; D011467:Prostate / Q000187:drug effects / Q000473:pathology / Q000528:radiation effects; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012189:Retrospective Studies; D012995:Solubility; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D001429:Bacteriochlorophylls; C503696:padeliporfin